NLRP3 and systemic lupus erythematosus: Researches demonstrate that rapamycin reduces NLRP3 inflammasome activation by inhibiting the mTOR/NF-κB pathway in macrophages (Dai et al., 2019), and mTOR regulates NLRP3 inflammasome activation via reactive oxygen species in murine lupus (Li et al., 2018).